Paige Mahaney

CIK: 0002040313

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CCCC

C4 Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

CCCC
C4 Therapeutics, Inc.
Feb 14, 2026
Exercise(M)
Direct
7.1K shares-
CCCC
C4 Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Direct
2.4K shares at avg. $1.89$5K
CCCC
C4 Therapeutics, Inc.
Feb 13, 2026
Award(A)
Direct
240K shares-
CCCC
C4 Therapeutics, Inc.
Oct 28, 2025
Exercise(M)
Direct
19.2K shares-
CCCC
C4 Therapeutics, Inc.
Oct 28, 2025
Tax Payment(F)
Direct
5.6K shares at avg. $2.58$15K
CCCC
C4 Therapeutics, Inc.
Feb 14, 2025
Award(A)
Direct
28.2K shares-
CCCC
C4 Therapeutics, Inc.
Oct 28, 2024
Award(A)
Direct
76.8K shares-

		Type	Shares	Price		Ownership
Feb 14, 2026	CCCC C4 Therapeutics, Inc.	Exercise(M)	7,050	-	$0	Direct
Feb 14, 2026	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	2,446	$1.89	$4,623	Direct
Feb 13, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	240,000	-	$0	Direct
Oct 28, 2025	CCCC C4 Therapeutics, Inc.	Exercise(M)	19,200	-	-	Direct
Oct 28, 2025	CCCC C4 Therapeutics, Inc.	Tax Payment(F)	5,644	$2.58	$14,562	Direct
Feb 14, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	28,200	-	-	Direct
Oct 28, 2024	CCCC C4 Therapeutics, Inc.	Award(A)	76,800	-	$0	Direct

1-7 of 7 transactions

About Mahaney Paige

Mahaney Paige (SEC CIK 0002040313) files insider reports with the SEC as Chief Scientific Officer of C4 Therapeutics, Inc. (CCCC).

Signal8 holds 5 ownership filings by Mahaney Paige (1 Form 3, 4 Form 4), filed between Oct 29, 2024 and Feb 18, 2026. Those filings report 7 transactions, from Oct 28, 2024 to Feb 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mahaney Paige's filings is in WATERTOWN, MA.

Recent filings by Mahaney Paige

Feb 14, 2026: Option exercise of CCCC shares (Form 4, code M).
Feb 14, 2026: Tax withholding of CCCC shares (Form 4, code F).
Feb 13, 2026: Grant or award of CCCC shares (Form 4, code A).
Oct 28, 2025: Option exercise of CCCC shares (Form 4, code M).
Oct 28, 2025: Tax withholding of CCCC shares (Form 4, code F).

Other insiders filing for C4 Therapeutics, Inc. (CCCC)

Anderson Kenneth Carl, Director
GROGAN DONNA ROY, Director
Adams Kendra, Chief Financial Officer
REYNO LEONARD, Chief Medical Officer
Hughes Owen, Director
Hoerter Steven L., Director

How to read Form 4 transaction codes